We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of bleeding in patients receiving direct oral anticoagulants.
- Authors
Hellenbart, Erika L.; Faulkenberg, Kathleen D.; Finks, Shannon W.
- Abstract
Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. As use of these anticoagulants has become favored over the past several years, reported bleeding-related adverse drug events with these agents has increased. In randomized clinical trials, all DOACs have a reduced risk for intracranial hemorrhage, while major and other bleeding results have varied among the agents compared to vitamin K antagonists. We have reviewed the bleeding incidence and severity from randomized and real-world data in patients receiving DOACs in an effort to provide the clinician with a critical review of bleeding and offer practical considerations for avoiding adverse events with these anticoagulants.
- Subjects
HEMORRHAGE diagnosis; EVIDENCE-based medicine; DABIGATRAN; RIVAROXABAN; APIXABAN; ANTICOAGULANTS; BLOOD coagulation; CLINICAL trials; COMMERCIAL product evaluation; COST effectiveness; DRUG side effects; HEMORRHAGE; MEDICAL care costs; ORAL drug administration; RISK assessment; TREATMENT effectiveness; DISEASE incidence; ACQUISITION of data; SEVERITY of illness index; ECONOMICS
- Publication
Vascular Health & Risk Management, 2017, Vol 13, p325
- ISSN
1176-6344
- Publication type
journal article
- DOI
10.2147/VHRM.S121661